Molecular Partners Ag (MOLN) Depreciation & Amortization (CF) (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Depreciation & Amortization (CF) of $639.78 for Q1 2026, up 4.2% year-on-year from $613.96 in Q1 2025, and up 100.05% on a QoQ basis from -$1.4 million in Q3 2025.
Molecular Partners Ag (MOLN) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Depreciation & Amortization (CF) for 6 consecutive years, with $639.78 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 639.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 639.78 |
| Mar 31, 2026 | 639.78 |
| Sep 30, 2025 | -1.38 Mn |
| Sep 30, 2025 | -1.38 Mn |
| Jun 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | 613.96 |
| Mar 31, 2025 | 613.96 |
| Sep 30, 2024 | -1.39 Mn |
| Sep 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 693.14 |
| Mar 31, 2024 | 693.14 |
| Sep 30, 2023 | -1.37 Mn |
| Sep 30, 2023 | -1.37 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 659.51 |
| Mar 31, 2023 | 659.51 |